Miami Cancer Institute Names Jeff Boyd, PH.D., Director of Translational Research and Genomic Medicine

Jeff Boyd, Ph.D., a renowned expert in cancer research and genetic testing, joins the executive leadership of Miami Cancer Institute at Baptist Health South Florida as director of translational research and genomic medicine. In this capacity, Dr. Boyd will play a critical role in positioning Miami Cancer Institute’s Center for Genomic Medicine as an international leader for highly personalized genetic analyses tailored to patients’ individual needs.

Dr. Boyd was most recently senior vice president for Molecular Medicine, executive director of the Cancer Genome Institute and the Robert C. Young, M.D., Chair in Cancer Research at Fox Chase Cancer Center in Philadelphia, where he also maintained a research laboratory. Previously, he served as attending biologist and director of the Diagnostic Molecular Genetics Laboratory and the Gynecology and Breast Research Laboratory at Memorial Sloan-Kettering Cancer Center in New York.

“We are extremely fortunate to have someone of Dr. Boyd’s caliber join our program,” said Leonard Kalman, M.D., deputy director and chief clinical officer of the Institute. “With his experience at two National Cancer Institute-designated centers and his reputation as an innovator in his field, Dr. Boyd will help us establish a world-class program in genomic medicine. He will foster important relationships with our academic alliance partner, as well as with other leaders in genomic medicine.”

Dr. Boyd is professor and chairman of the Department of Human and Molecular Genetics at Florida International University’s Herbert Wertheim College of Medicine. He serves on the editorial board of the American Journal of Pathology and has held faculty positions at Memorial Sloan-Kettering Cancer Center, the University of Pennsylvania and the National Institutes of Health.

A native of Chapel Hill, North Carolina, Dr. Boyd received his bachelor’s degree from Duke University, and his master’s and doctorate degree in toxicology/biochemistry from North Carolina State University in Raleigh.

About Miami Cancer Institute
Miami Cancer Institute offers comprehensive cancer services and is expanding its clinical services, clinical trials and state-of-the-art technology, including offering the first proton therapy treatment in South Florida, Latin America and the Caribbean. The Cancer Institute, designed to be a world-class clinical center and research destination, will move into its new spectacular facility in 2016.

Miami Cancer Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children’s Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital) and nearly 50 outpatient and urgent care facilities spanning three counties. The not-for-profit, faith-based Baptist Health has more than 16,000 employees and 2,200 affiliated physicians and also includes Baptist Health Medical Group, Baptist Health Quality Network, Baptist Outpatient Services and internationally renowned centers of excellence. Baptist Health Foundation, the organization’s fundraising arm, supports services at all hospitals and facilities. Baptist Health is listed by Fortune magazine as one of the 100 Best Companies to Work For in America (#23 in the nation) and has remained on the list for 15 years. It was also recognized as one of the World’s Most Ethical Companies for the fourth year in a row by the Ethisphere Institute. Visit BaptistHealth.net.